REBETOL

Phase 3Small molecule

Merck & Co.

REBETOL is one of 63 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

REBETOL

Merck & Co.

Phase 3

12 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis12 trials

Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Completed· Merck & Co. logo

Merck & Co.··NCT00709228·496 enrolled

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00441584·117 enrolled

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00724230·505 enrolled

Show 9 more trials

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00081770·4,469 enrolled

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.··NCT00727077·3 enrolled

Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00727311·2,302 enrolled

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00039871·2,333 enrolled

An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)

Withdrawn· Merck & Co. logo

Merck & Co.··NCT00704756

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)

Completed· Merck & Co. logo

Merck & Co.··NCT00709059·538 enrolled

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

Completed· Merck & Co. logo

Merck & Co.··NCT00725205·294 enrolled

Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)

Completed· Merck & Co. logo

Merck & Co.··NCT00726557·246 enrolled

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Completed· Merck & Co. logo

Merck & Co.··NCT00724464·332 enrolled

Hepatitis C4 trials

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00811967·50 enrolled

Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)

Completed· Merck & Co. logo

Merck & Co.··NCT00723892·614 enrolled

Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)

Completed· Merck & Co. logo

Merck & Co.··NCT00704717·185 enrolled

Show 1 more trial

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Terminated· Merck & Co. logo

Merck & Co.··NCT00705107·267 enrolled

TED2 trials

Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)

Completed· Merck & Co. logo

Merck & Co.··NCT00724854·1,146 enrolled

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

Completed· Merck & Co. logo

Merck & Co.··NCT00728494·99 enrolled

Treatment1 trial

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

Completed· Pfizer logo

Pfizer·Phase 2·NCT00367887·246 enrolled

MPA1 trial

Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)

Completed· Merck & Co. logo

Merck & Co.··NCT00704964·746 enrolled

1 more indication

Fasting Conditions1 trial

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00960479·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for REBETOL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REBETOL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REBETOL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

REBETOL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis12 trials

Hepatitis C4 trials

TED2 trials

Treatment1 trial

MPA1 trial

Fasting Conditions1 trial

References

Drug Info

Quick Facts

Related News